TOP > 外国特許検索 > ANTI-HUMAN NOROVIRUS AGENT

ANTI-HUMAN NOROVIRUS AGENT NEW

外国特許コード F200010208
整理番号 (S2019-0175-N0)
掲載日 2020年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP051496
国際公開番号 WO 2020138447
国際出願日 令和元年12月27日(2019.12.27)
国際公開日 令和2年7月2日(2020.7.2)
優先権データ
  • 特願2018-244213 (2018.12.27) JP
発明の名称 (英語) ANTI-HUMAN NOROVIRUS AGENT NEW
発明の概要(英語) The present invention addresses the problem of providing an anti-human norovirus agent capable of suppressing infection and growth of human norovirus. The present inventers have discovered that said problem can be solved by providing an anti-human norovirus agent that contains, as an active ingredient, a fucose analog having an activity of inhibiting glycosylation by fucose transferase (FUT). The active ingredient is, for example, a fucose analog represented by formula (III) or (IV), or a salt thereof (wherein, formula (III) or (IV) respectively represent an α- or β-anomer, R1, R3, and R4 each represent–OH or –OAc, R2 represents a halogen atom, -OH, or –OAc, R5 represents -CH3, -C≡CH, -C≡CCH3, or -CH2C≡CH).
従来技術、競合技術の概要(英語) BACKGROUND ART
Norovirus (Norovirus) is 1 of 4 viruses belonging to the caliciviridae family, and Norwalk virus (Norwalk virus) is only the virus species currently.
Human norovirus is infected mainly through food (fish and shellfish or water), and can be infected even with a small amount of about 100-1000 virus particles in the food, and has very strong infective power. Food poisoning by human norovirus occupies 90 % or more of viral food poisoning.
The major symptoms of human norovirus infection are nausea, vomiting, diarrhea, and fever. Vomiting and diarrhea are more than 10 times when they are several times a day, and eels may be mixed with bile and intestinal substances, which are considered to be severe pain.
In North American data, about 2000 million persons suffer from human norovirus infection for, years, about 200 million persons were consulted at hospitals, 40 million persons were first carried, million persons were hospitalized, and 7000 persons were dead for, years.
Vomiting diarrhea caused by human norovirus infection in Japan has been increasing to 100-300 million people over several tens of years by the estimation of National Institute of infection. As a result, there is a high demand for antiviral drugs and vaccines against human noroviruses from Japan, and the order of development priority is located at the 4 th position in administrative administration. In Japan, there are few cases where human norovirus infection is a direct cause of death, but in the case of other diseases and elderly people, there is a high risk of prolongation and severity. In addition, even if the symptoms described above are settled, excretion of human norovirus having a very strong infectious power into feces lasts for 7-14 days or for 2 months or longer in the case of a long period of time, and it is impossible to return to schools or workplaces during that period. In addition, insensible infected persons of human norovirus are always detected at a rate of several percent of the total population. Since an insensible infected person of human norovirus is not aware of viral infection by the infected person itself, it has been reported that, for example, the insensible infected person acts as a food worker to cause large-scale food poisoning.
As described above, human norovirus is a food-toxic virus which has a high frequency of morbidity and is accompanied by pain of a patient, and is a virus which has a strong infectivity and is recognized to be insensible infection, but there is no special effect drug at present. Through hydration by oral or drip infusion or the like, progress observation is basic while preventing dehydration, and other measures such as administration of an antiemetic agent and an enteric agent are performed. In this paper, we propose a new method for the prevention of virus infection in the intestinal tract.
In 2002 years, the French group reported that the virus-like hollow particle (VLP) of human norovirus binds to human tissue blood group antigen (HBGA), and it was suggested that this molecule may be a receptor of human norovirus.
Subsequently, verification by human volunteers proceeds, and it was clarified that HBGA non-secretory individuals (non-secretor individual) are less susceptible to human norovirus and HBGA secretory individuals (secretor individual) are susceptible to human norovirus.
However, at present, HBGA itself is not a receptor responsible for the invasion of human norovirus into cells. This is due to the following reasons.
That is, whether or not HBGA is secreted into saliva and mucous membrane is considered to be related to the genetic polymorphism of 2 position) among FUT2 (fucosyltransferase positions 2 and 1-8. However, even if the FUT2 gene is introduced into a cell in which HBGA is not expressed on the cell surface to secrete HBGA and express HBGA on the cell surface, infection with human norovirus to the cell is not established. Therefore, HBGA itself is not said to be a receptor responsible for invasion of human norovirus into cells, and the causal relationship (directly and indirectly between FUT2 gene polymorphism and human norovirus infection susceptibility has not yet been elucidated.
Patent Document 1 is a prior art document in which applications of anticancer agents are disclosed mainly for the active ingredient of the anti-norovirus agent of the present invention described below. In Patent Document 1, a general description of use in treating infectious diseases is recognized, but examples are not disclosed. In addition, noroviruses and related diarrhea viruses are not disclosed among the viruses listed in Patent Document 1, and the mechanism of action in paired infections described in Patent Document 1 is the enhancement of immune response, which is completely different from the anti-norovirus agent of the present invention.
Patent Document 2 describes 2 D set used in the examples.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KEIO UNIVERSITY
  • THE KITASATO INSTITUTE
  • 発明者(英語)
  • KATAYAMA Kazuhiko
  • FUJIMOTO Akira
  • HAGA Kei
  • TODAKA Reiko
  • SATO Toshiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close